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lecting meaningful and responsive quality of life instru-
ments for use in clinical trials and other evaluative studies.
Health outcomes and quality of life assessment is becom-
ing increasingly important in the evaluation of pharma-
ceutical products, in terms of labeling claims and product
promotion as well as in terms of formulary decisions.
Each of these uses requires an assessment strategy that
provides information relevant for decision-making. What
are the components of a successful strategy? How is a
given strategy evaluated to select the best for the given
evaluative study? This workshop will address these ques-
tions and introduce an analytic framework that partici-
pants can apply in their daily experience.
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WORKSHOP OBJECTIVE: The purpose of this work-
shop is to demonstrate, using a schizophrenia case study,
how prevalence-based drug value information can be pre-
sented in a format that is understandable and useful for
decision-makers.
PARTICIPANTS WHO WOULD BENEFIT: Those who
want to learn a process that will increase the likelihood
that prevalence-based drug value analyses are used by de-
cision-makers.
Although many drug value analyses have been completed
in recent years, it is not clear to what extent these analy-
ses have been used to inform decisions. In a recent paper,
Mauskopf (VH 1998) has suggested that prevalence-
based annual estimates of population and cost outcomes
would be of value to decision-makers. In this workshop,
we will take the participants through a series of activities
designed to ensure that decision-makers can understand
and use the results of prevalence-based drug value analy-
ses. We will illustrate these activities using a project that
we recently completed for schizophrenia. In this project,
we developed an interactive computer model to estimate
the impacts of the atypical anti-psychotics on patient and
family outcomes and healthcare costs for a population of
schizophrenia patients. The project included three main
activities: 1) develop a preliminary model; 2) present the
model to decision-makes to determine its value to them;
and 3) revise the model based on decision-maker com-
ments and create an interactive computer version of the
model. We will show the workshop participants how we
presented our model to the decision-makers. We will
summarize the decision-makers responses to the presen-
tation. We will then lead the workshop participants in a
discussion about the range of possible responses to these
comments and the trade-offs between 1) keeping a model
well grounded in published literature; and 2) extrapolating
information to address outcomes that are important to de-
cision-makers, but not well researched. We will conclude
the workshop by describing how we modified the prelimi-
nary model in response to the decision-makers’ comments
and by showing the final interactive computer model.
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WORKSHOP OBJECTIVE: To highlight design features
that characterize state-of-the-art studies evaluating out-
comes of competing pharmacotherapies, balancing the need
to maintain internal validity with the goal of providing in-
formation that can be applied to the “real world” of clinical
practices.
PARTICIPANTS WHO WOULD BENEFIT: 1) Out-
comes researchers, statisticians, health economists, and
others who wish to expand beyond the traditional clini-
cal trial design; and 2) clinicians, healthcare organiza-
tions, and others who wish to learn more about how to
make informed decisions based on comparative cost and
effectiveness claims.
Various methodological issues are critical in the design of
naturalistic outcomes trials. These include how narrowly
(or broadly) to define the patient population, whether or
not to “blind” the study, how much physician discretion
to allow in treating patients, and how to obtain and ana-
lyze data on patients who switch from their originally-as-
signed medication (or on patients who discontinue medi-
cation). Additionally, the definition of comparator(s) and
the appropriate time horizon of the study are important.
These and other issues will be discussed and illustrated
through examples of two randomized naturalistic trials de-
signed by the workshop leaders and colleagues. One study
is designed to answer the question of whether using an
atypical antipsychotic agent as first-line therapy is more ef-
fective and less costly than requiring a patient to first fail
on conventional medications. The other study is designed
to determine how three different selective serotonin re-
uptake inhibitors compare in terms of various outcome
measures including patient adherence, quality of life, and
resource utilization. The authors will discuss the decisions
made in designing these trials and the implications of these
decisions for data analysis and interpretation of findings.
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